当它"计数"时的疼痛:临床疼痛评级的障碍分析改善了数据模型性能
Beth B Hogans1,2, Bernadette C Siaton3,4, John D Sorkin1,5
1Geriatric Research Education and Clinical Center, VA Maryland Health Care System, Baltimore, MD, United States.
Pain reports
|August 11, 2025
概括
障碍分析提供了一种更好的方法来评估慢性疼痛,通过分离零和非零的疼痛评级,减少患者报告的结果的变化,例如腰部疼痛.
科学领域:
- 疼痛研究 疼痛研究
- 生物统计学 生物统计学
- 医疗信息学 医疗信息学
背景情况:
- 数值评分表是疼痛强度的标准,但由于单个疼痛评分的高变化,慢性疼痛有局限性.
- 准确评估慢性疼痛对于有效的患者管理和治疗至关重要.
研究的目的:
- 引入和评估障碍分析作为评估慢性疼痛强度的改进方法.
- 将障碍分析与传统方法进行比较,使用大量患者报告的疼痛评级数据集.
主要方法:
- 一项回顾性研究分析了来自23480名美国退伍军人腰部疼痛 (LBP) 的210万个疼痛评级.
- 障碍分析被用来单独建模零 (没有疼痛) 和非零 (存在疼痛) 疼痛评级.
- 疼痛评级的边际分布是使用标准和障碍分析方法进行参数化的.
主要成果:
- 在研究人群中,79%的男性和73%的女性的模式值是零疼痛.
- 障碍分析显示,零疼痛评级的平均比例为男性0.39,女性0.31.
- 平均非零疼痛评级为男性5.9,女性6.0,分布正常分布,比标准平均值更少偏差.
结论:
- 障碍分析提供了更准确的疼痛强度估计,当疼痛存在 (非零疼痛).
- 这种方法有效地捕捉了患有LBP等慢性疾病的人群中疼痛的可变存在.
- 这些发现支持进一步研究临床疼痛评估的障碍分析.
相关概念视频
Analgesia and Pain Management
791
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
791
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
124
Noncompartmental analyses offer an alternative method for describing drug pharmacokinetics without relying on a specific compartmental model. In this approach, the drug's pharmacokinetics are assumed to be linear, with the terminal phase log-linear. This assumption allows for simplified analysis and interpretation of the drug's behavior in the body.
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This...
124


